Evidence map›Paper›PMID 41404513›Full record

Trial reportFrontiers in endocrinology2025

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.

Maciej Kolodziej, Marta Opalinska, Renata Mikolajczak, Alicja Hubalewska-Dydejczyk, Marek Dedecjus, Aldona Kowalska, Marek Saracyn, Piotr Garnuszek, Izabela Cieszykowska, Joanna Januszkiewicz-Caulier and 20 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Long-term toxicity of tandem radioligand therapy using [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Maciej KolodziejDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Marta OpalinskaChair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland.
Renata MikolajczakRadioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland.
Alicja Hubalewska-DydejczykChair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland.
Marek DedecjusDepartment of Endocrine Oncology and Nuclear Medicine, National Institute of Oncology - National Research Institute, Warsaw, Poland.
Aldona KowalskaCollegium Medicum, Jan Kochanowski University, Kielce, Poland.
Marek SaracynDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Piotr GarnuszekRadioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland.
Izabela CieszykowskaRadioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland.
Joanna Januszkiewicz-CaulierDepartment of Endocrine Oncology and Nuclear Medicine, National Institute of Oncology - National Research Institute, Warsaw, Poland.
Joanna DlugosinskaDepartment of Endocrine Oncology and Nuclear Medicine, National Institute of Oncology - National Research Institute, Warsaw, Poland.
Adam Daniel DurmaDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Katarzyna Jozwik-PlebanekDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Adrianna MrozDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Katarzyna JaniakDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Danuta Gasior-PerczakCollegium Medicum, Jan Kochanowski University, Kielce, Poland.
Malgorzata Trofimiuk-MuldnerChair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland.
Anna Sowa-StaszczakChair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland.
Janusz BraziewiczDepartment of Nuclear Medicine, Holy Cross Cancer Center, Kielce, Poland.
Wioletta Lenda-TraczFaculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland.
Krzysztof KacperskiParticle Acceleration Physics and Technology Division, National Centre for Nuclear Research, Otwock, Poland.
Anna BudzynskaDepartment of Nuclear Medicine, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Agata KubikDepartment of Nuclear Medicine, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Patrycja PastusiakDepartment of Nuclear Medicine, Military Institute of Medicine - National Research Institute, Warsaw, Poland.
Wioletta ChalewskaDepartment of Endocrine Oncology and Nuclear Medicine, National Institute of Oncology - National Research Institute, Warsaw, Poland.
Anna BorkowskaFaculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland.
Paulina CeglaDepartment of Endocrine Oncology and Nuclear Medicine, National Institute of Oncology - National Research Institute, Warsaw, Poland.
Agata Walecka-MazurDepartment of Endocrinology, Holy Cross Cancer Center, Kielce, Poland.
Artur SzczodryDepartment of Endocrinology, Holy Cross Cancer Center, Kielce, Poland.
Grzegorz KaminskiDepartment of Endocrinology and Isotope Therapy, Military Institute of Medicine - National Research Institute, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: PRRT with [ Methods: DUONEN is an ongoing multicenter, randomized phase 3 trial (N = 92 planned; 56 analyzed) comparing standard fixed-activity [ Results: Activity reductions predominated in arms B and C, while increases were common in arm D. Median cumulative kidney and marrow doses were highest in arm C (29.1 Gy and 0.79 Gy, respectively), driven by Conclusions: This interim analysis demonstrates the feasibility and safety of dosimetry-guided PRRT strategies, including individualized Clinical trial registration: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-006068-99, identifier 2020-006068-99.

Indexed as

Intestinal NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsRadioisotopesRadiopharmaceuticalsReceptors, PeptideStomach NeoplasmsAdultAgedFemaleHumansLutetiumMaleMiddle AgedOctreotideOrganometallic CompoundsLutetiumLutetium-177OctreotideOrganometallic CompoundsRadioisotopesRadiopharmaceuticalsReceptors, PeptideYttrium-90Yttrium Radioisotopes[177Lu]Lu-DOTA-TATE[90Y]Y-DOTA-TATEdosimetryGEP-NETNETPRRTRLTtandem therapy

Identifiers

PMID41404513
PMCPMC12702747

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.